CRVO ▼ -0.3% - CervoMed Inc.
$CRVO - CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
12-OCT-2026 07:30 AM ET
Share this post
More filings for $CRVO
CRVO ▲ +3.4% - CervoMed Inc.Sep 29, 2026CRVO ▲ +6.3% - CervoMed Inc.Sep 28, 2026CRVO ▼ -0.4% - CervoMed Inc.Sep 22, 2026CRVO ▲ +1.6% - CervoMed Inc.Sep 10, 2026CRVO ▲ +0.8% - CervoMed Inc.Sep 8, 2026CRVO - CervoMed Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $CRVO filing history →💬 Comments
Loading comments…
Leave a comment